BR112016008082A2 - métodos para tratamento de doença pulmonar obstrutiva crônica usando benralizumab - Google Patents

métodos para tratamento de doença pulmonar obstrutiva crônica usando benralizumab

Info

Publication number
BR112016008082A2
BR112016008082A2 BR112016008082A BR112016008082A BR112016008082A2 BR 112016008082 A2 BR112016008082 A2 BR 112016008082A2 BR 112016008082 A BR112016008082 A BR 112016008082A BR 112016008082 A BR112016008082 A BR 112016008082A BR 112016008082 A2 BR112016008082 A2 BR 112016008082A2
Authority
BR
Brazil
Prior art keywords
benralizumab
methods
pulmonary disease
chronic obstructive
obstructive pulmonary
Prior art date
Application number
BR112016008082A
Other languages
English (en)
Portuguese (pt)
Inventor
Wang Bing
Ward Christine
Roskos Lorin
Van Der Merwe Rene
Martin Ubaldo
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of BR112016008082A2 publication Critical patent/BR112016008082A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112016008082A 2013-10-15 2014-10-14 métodos para tratamento de doença pulmonar obstrutiva crônica usando benralizumab BR112016008082A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361891175P 2013-10-15 2013-10-15
US201461970126P 2014-03-25 2014-03-25
PCT/US2014/060432 WO2015057668A1 (en) 2013-10-15 2014-10-14 Methods for treating chronic obstructive pulmonary disease using benralizumab

Publications (1)

Publication Number Publication Date
BR112016008082A2 true BR112016008082A2 (pt) 2017-10-17

Family

ID=52809872

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016008082A BR112016008082A2 (pt) 2013-10-15 2014-10-14 métodos para tratamento de doença pulmonar obstrutiva crônica usando benralizumab

Country Status (12)

Country Link
US (4) US20150104447A1 (https=)
EP (2) EP3485902A1 (https=)
JP (3) JP2016534996A (https=)
KR (1) KR20160061352A (https=)
CN (2) CN113230399A (https=)
AU (2) AU2014334563A1 (https=)
BR (1) BR112016008082A2 (https=)
CA (1) CA2925402A1 (https=)
MX (2) MX2016004329A (https=)
RU (1) RU2706729C2 (https=)
SG (2) SG10201807318RA (https=)
WO (1) WO2015057668A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2687043C2 (ru) 2013-04-29 2019-05-06 Ф. Хоффманн-Ля Рош Аг МОДИФИЦИРОВАННЫЕ АСИММЕТРИЧНЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ Fc-РЕЦЕПТОР, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
KR20210094669A (ko) 2013-04-29 2021-07-29 에프. 호프만-라 로슈 아게 인간 fcrn-결합 변형된 항체 및 사용 방법
RU2698969C2 (ru) 2014-01-15 2019-09-02 Ф.Хоффманн-Ля Рош Аг Варианты fc-области с улучшенной способностью связываться с белком а
AU2016272399B2 (en) 2015-06-01 2021-09-09 Kyowa Kirin Co., Ltd. Therapeutic agent and therapeutic method for pulmonary hypertension
CN109544378B (zh) * 2018-10-27 2024-06-25 平安医疗健康管理股份有限公司 一种肺源性心脏病资质认证方法、设备及服务器
TW202110479A (zh) * 2019-05-16 2021-03-16 瑞典商阿斯特捷利康公司 使用貝那利珠單抗治療增強型患者群體慢性阻塞性肺病之方法
BR112022010934A2 (pt) * 2019-12-06 2022-11-29 Sanofi Biotechnology Métodos para tratar copd administrando um antagonista de il-33
EP3957308A1 (en) 2020-08-21 2022-02-23 Palobiofarma, S.L. (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases
WO2023034993A1 (en) * 2021-09-03 2023-03-09 Gleich Gerald J Compositions and methods for diagnosing, detecting and treating eosinophil-related diseases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1241944C (zh) * 1995-09-11 2006-02-15 协和发酵工业株式会社 抗人白介素－5受体α链的抗体
EP1176195B1 (en) * 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US7404953B2 (en) * 2000-02-15 2008-07-29 Kyowa Hakko Kogyo Co., Ltd. Methods using eosinophil-specific apoptosis inducer
US6946292B2 (en) * 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7662925B2 (en) * 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US20060014680A1 (en) * 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
HUE036885T2 (hu) * 2007-05-14 2018-08-28 Astrazeneca Ab Eljárás a bazofil-szint csökkentésére
CN101249093A (zh) * 2008-03-19 2008-08-27 李虎山 一种治疗慢性阻塞性肺部疾病的组合物
MX2013004212A (es) * 2010-10-15 2013-09-02 Medimmune Ltd Terapias para mejorar la funcion pulmonar.
TWI732259B (zh) * 2010-12-16 2021-07-01 美商建南德克公司 關於th2抑制作用之診斷及治療
EP2710370A4 (en) * 2011-05-18 2015-01-07 Medimmune Llc METHODS OF DIAGNOSING AND TREATING PULMONARY DISEASES OR DISORDERS
HK1201440A1 (en) * 2011-11-01 2015-09-04 Medimmune, Llc Methods for reducing the frequency and severity of acute exacerbations of asthma
CN111617244A (zh) * 2013-08-12 2020-09-04 阿斯特拉捷利康股份公司 使用贝那利珠单抗改善哮喘症状的方法
CA2918105C (en) * 2013-08-12 2023-02-28 Medimmune, Llc Methods for reducing exacerbation rates of asthma using benralizumab
US9441046B2 (en) * 2013-08-12 2016-09-13 Astrazeneca Ab Methods for increasing forced expiratory volume in asthmatics using benralizumab

Also Published As

Publication number Publication date
AU2014334563A1 (en) 2016-04-07
SG11201601807XA (en) 2016-04-28
JP6870037B2 (ja) 2021-05-12
MX2016004329A (es) 2016-11-10
RU2016118425A3 (https=) 2018-07-19
KR20160061352A (ko) 2016-05-31
JP2016534996A (ja) 2016-11-10
MX2019013468A (es) 2020-02-12
JP2019203009A (ja) 2019-11-28
RU2706729C2 (ru) 2019-11-20
JP2021107421A (ja) 2021-07-29
CA2925402A1 (en) 2015-04-23
CN113230399A (zh) 2021-08-10
EP3057609A1 (en) 2016-08-24
US20180291108A1 (en) 2018-10-11
US20200123262A1 (en) 2020-04-23
RU2016118425A (ru) 2017-11-21
SG10201807318RA (en) 2018-09-27
EP3485902A1 (en) 2019-05-22
CN105636607A (zh) 2016-06-01
US20150104447A1 (en) 2015-04-16
EP3057609A4 (en) 2017-03-22
AU2020202333A1 (en) 2020-04-23
US20170107291A1 (en) 2017-04-20
WO2015057668A1 (en) 2015-04-23

Similar Documents

Publication Publication Date Title
BR112016008082A2 (pt) métodos para tratamento de doença pulmonar obstrutiva crônica usando benralizumab
MX2023000079A (es) Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento de sinusitis cronica con polipos nasales.
MX2016002826A (es) Anticuerpos anti-b7-h1 para tratar tumores.
CY1121203T1 (el) Θεραπευτικες χρησεις της εμπαγλιφλοζινης
BR112015022197A2 (pt) tratamento de cataplexia
MX2014010481A (es) Nuevas composiciones para el tratamiento de la esclerosis lateral amiotrofica.
BR112017016952A2 (pt) terapia de combinação com fatores de coagulação e anticorpos multiespecíficos
MX2017016253A (es) Anticuerpos para cd40.
CY1121710T1 (el) Παρεμβασεις με βαση την αγγειοποιητινη για τη θεραπεια της εγκεφαλικης ελονοσιας
MX368068B (es) Antagonista de il-4r para usarse para tratar la poliposis nasal.
EA201691481A1 (ru) ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
BR112018003526A2 (pt) métodos de tratamento de doenças inflamatórias
MX2014004074A (es) Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
BR112016002317A2 (pt) métodos para aumentar o volume expiratório forçado em asmáticos usando benralizumab
NZ629828A (en) Methods for the treatment of b cell-mediated inflammatory diseases
TN2015000277A1 (en) Bmp-6 antibodies
EA201590883A1 (ru) Лечение помалидомидом рака у субъекта с почечной недостаточностью
MX368474B (es) Uso de benralizumab para mejorar síntomas de asma.
EA201792282A1 (ru) Способы лечения заболеваний
BR112017016347A2 (pt) ?novas composições e métodos para o tratamento e/ou prevenção de doença pulmonar obstrutiva crônica?
BR112016016098A2 (pt) Compostos orgânicos
EA201491581A1 (ru) Везикулярные композиции
EA201690446A1 (ru) Лечение множественной миеломы
EA201690445A1 (ru) Лечение рака
EA202090453A3 (ru) Антитела к cd40

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: ASTRAZENECA AB (SE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.